Search hospitals > North Carolina > Raleigh
Duke University Health System
Claim this profileRaleigh, North Carolina 27615
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Glioblastoma
Conducts research for Brain Tumor
Conducts research for Non-Small Cell Lung Cancer
198 reported clinical trials
25 medical researchers
Summary
Duke University Health System is a medical facility located in Raleigh, North Carolina. This center is recognized for care of Cancer, Lung Cancer, Glioblastoma, Brain Tumor, Non-Small Cell Lung Cancer and other specialties. Duke University Health System is involved with conducting 198 clinical trials across 489 conditions. There are 25 research doctors associated with this hospital, such as Jeffrey Crawford, Angeles A. Secord, Harry P. Erba, and Cristina Gasparetto, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage III
Stage II
Stage I
Top PIs
Jeffrey CrawfordDuke University Medical Center5 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
21 reported clinical trials
57 drugs studied
Angeles A. SecordDuke University Medical Center3 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
16 reported clinical trials
30 drugs studied
Harry P. ErbaDuke University Medical Center5 years of reported clinical research
Expert in Leukemia
Studies Acute Myeloid Leukemia
14 reported clinical trials
26 drugs studied
Cristina Gasparetto, MDDuke University Hospital2 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
9 reported clinical trials
19 drugs studied
Clinical Trials running at Duke University Health System
Non-Small Cell Lung Cancer
Prostate Cancer
Lung Cancer
Melanoma
Brain Tumor
Gallbladder Cancer
Cancer
Cutaneous Melanoma
Pancreatic Cancer
Ovarian Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Duke University Health System?
Duke University Health System is a medical facility located in Raleigh, North Carolina. This center is recognized for care of Cancer, Lung Cancer, Glioblastoma, Brain Tumor, Non-Small Cell Lung Cancer and other specialties. Duke University Health System is involved with conducting 198 clinical trials across 489 conditions. There are 25 research doctors associated with this hospital, such as Jeffrey Crawford, Angeles A. Secord, Harry P. Erba, and Cristina Gasparetto, MD.